SCHEMBL16410263

SCHEMBL16410263

CN(CC1CCCC1)c1cc(Cl)cc(COc2ccccc2CC(=O)OC(C)(C)C)c1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 1/20 0.37
▸ HTR2C P28335 3/20 0.35
▸ SLC6A4 P31645 3/20 0.35
▸ HTR2A P28223 1/20 0.35
▸ S1PR1 P21453 2/20 0.35
▸ CACNA1B Q00975 2/20 0.35
▸ PTGER1 P34995 2/20 0.34
▸ CARM1 Q86X55 2/20 0.34
▸ PRMT1 Q99873 2/20 0.34
▸ TRPM8 Q7Z2W7 2/20 0.34
▸ CFD P00746 2/20 0.33
▸ F11 P03951 2/20 0.33
▸ KLKB1 P03952 2/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ HRH3 Q9Y5N1 1/20 0.33
▸ SLC1A5 Q15758 1/20 0.33
▸ MTNR1A P48039 1/20 0.33
▸ MTNR1B P49286 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16397592 0.88 CFD (0.42) TRPV1PTGER1CARM1PRMT1CFD
SCHEMBL16410379 0.88 GAA (0.42) HTR2CSLC6A4
SCHEMBL16396435 0.86 TRPM8 (0.35) S1PR1PTGER1CARM1PRMT1TRPM8
SCHEMBL16396642 0.82 PTGER1 (0.36) CACNA1BPTGER1CFDF11KLKB1
SCHEMBL16396785 0.78 POLB (0.36) PTGER1CFDF11KLKB1CYP2C9
SCHEMBL17772645 0.78 CACNA1B (0.38) TRPV1CACNA1BPTGER1CFDF11
SCHEMBL16397377 0.77 CFD (0.43) PTGER1CFDF11KLKB1CYP2C9
SCHEMBL16396268 0.76 MEN1 (0.40) PTGER1CYP2C9
SCHEMBL16410429 0.75 MEN1 (0.43) PTGER1CYP2C9MTNR1AMTNR1B
SCHEMBL16396265 0.75 MTNR1A (0.40) PTGER1CFDF11KLKB1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof CFD, CFH, CFB TRPV1 4853/4885HTR2C 2054/4885SLC6A4 3981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback